[go: up one dir, main page]

PT4051688T - Inibidores de cd73 - Google Patents

Inibidores de cd73

Info

Publication number
PT4051688T
PT4051688T PT208832881T PT20883288T PT4051688T PT 4051688 T PT4051688 T PT 4051688T PT 208832881 T PT208832881 T PT 208832881T PT 20883288 T PT20883288 T PT 20883288T PT 4051688 T PT4051688 T PT 4051688T
Authority
PT
Portugal
Prior art keywords
inhibitors
Prior art date
Application number
PT208832881T
Other languages
English (en)
Original Assignee
Oric Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oric Pharmaceuticals Inc filed Critical Oric Pharmaceuticals Inc
Publication of PT4051688T publication Critical patent/PT4051688T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT208832881T 2019-10-30 2020-10-29 Inibidores de cd73 PT4051688T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962928138P 2019-10-30 2019-10-30
US202062987806P 2020-03-10 2020-03-10
US202063088646P 2020-10-07 2020-10-07

Publications (1)

Publication Number Publication Date
PT4051688T true PT4051688T (pt) 2025-06-30

Family

ID=75686256

Family Applications (1)

Application Number Title Priority Date Filing Date
PT208832881T PT4051688T (pt) 2019-10-30 2020-10-29 Inibidores de cd73

Country Status (19)

Country Link
US (6) US11530236B2 (pt)
EP (2) EP4051688B1 (pt)
JP (2) JP7544815B2 (pt)
KR (2) KR102727229B1 (pt)
CN (2) CN116854758A (pt)
AU (1) AU2020375914B2 (pt)
CA (1) CA3159248C (pt)
DK (1) DK4051688T3 (pt)
ES (1) ES3034168T3 (pt)
FI (1) FI4051688T3 (pt)
HU (1) HUE072504T2 (pt)
IL (2) IL292570B2 (pt)
MX (1) MX2022005256A (pt)
PL (1) PL4051688T3 (pt)
PT (1) PT4051688T (pt)
SI (1) SI4051688T1 (pt)
TW (1) TWI830962B (pt)
WO (1) WO2021087136A1 (pt)
ZA (1) ZA202204941B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11129841B2 (en) 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
WO2019090111A1 (en) 2017-11-03 2019-05-09 Oric Pharmaceuticals, Inc. Cd73 inhibitors
KR20210018255A (ko) 2018-04-30 2021-02-17 오릭 파마슈티칼스, 인크. Cd73 억제제
TWI830962B (zh) * 2019-10-30 2024-02-01 美商歐瑞克製藥公司 Cd73抑制劑
CA3256033A1 (en) 2022-04-13 2023-10-19 Arcus Biosciences, Inc. POLYTHERAPY FOR THE TREATMENT OF CANCERS EXPRESSING TOO MUCH-2
KR20250078473A (ko) * 2022-09-14 2025-06-02 오릭 파마슈티칼스, 인크. Cd73 억제제의 약학적 형태
US20240140979A1 (en) * 2022-10-03 2024-05-02 Teon Therapeutics, Inc. Heterocyclic inhibitors of cd73 for treatment of disease
WO2024076873A1 (en) * 2022-10-03 2024-04-11 Teon Therapeutics, Inc. Heterocyclic inhibitors of cd73 for treatment of disease
WO2025111247A1 (en) * 2023-11-20 2025-05-30 Oric Pharmaceuticals, Inc. Treatment of refractory multiple myeloma
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025233264A1 (en) 2024-05-07 2025-11-13 Innate Pharma Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1023991A (en) 1911-07-29 1912-04-23 Firm B Byers Anti-rail-creeper and splice-bar.
EP0477454A1 (en) 1990-09-28 1992-04-01 Merrell Dow Pharmaceuticals Inc. Novel phosphonate derivatives of certain nucleosides
EP1366055A2 (en) 2000-12-15 2003-12-03 Pharmasset Limited Antiviral agents for treatment of flaviviridae infections
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
WO2007139946A2 (en) 2006-05-25 2007-12-06 University Of Tennessee Research Foundation Gpcr ligands identified by computational modeling
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
US20090274686A1 (en) 2008-05-02 2009-11-05 Yat Sun Or Nucleoside phosphonate derivatives
JP6657182B2 (ja) * 2014-04-25 2020-03-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌治療用のcd73阻害剤としてのプリン誘導体
CN104530166B (zh) 2014-12-04 2016-08-24 陕西汉江药业集团股份有限公司 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法
EA036379B1 (ru) * 2014-12-12 2020-11-02 Блубёрд Био, Инк. Химерные антигенные рецепторы к bcma
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
HUE063388T2 (hu) 2016-01-08 2024-01-28 Arcus Biosciences Inc Ekto-5'-nukleotidáz modulátorok és ezek alkalmazása
CN110234656B (zh) * 2016-09-09 2023-02-28 卡利泰拉生物科技公司 外核苷酸酶抑制剂及其使用方法
WO2018067424A1 (en) * 2016-10-03 2018-04-12 Arcus Biosciences, Inc. Inhibitors of adenosine 5'-nucleotidase
EP3541396A4 (en) * 2016-11-18 2020-07-22 Arcus Biosciences, Inc. CD73-MEDIATED IMMUNOSUPPRESSION INHIBITORS
MX383880B (es) 2016-12-22 2025-03-14 Antengene Therapeutics Ltd Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
US20200115404A1 (en) * 2017-03-31 2020-04-16 Peloton Therapeutics, Inc. Cd73 inhibitors and uses thereof
WO2018208727A1 (en) * 2017-05-08 2018-11-15 Eternity Bioscience Inc. Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof
US11129841B2 (en) 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
WO2019090111A1 (en) * 2017-11-03 2019-05-09 Oric Pharmaceuticals, Inc. Cd73 inhibitors
WO2019129059A1 (zh) 2017-12-29 2019-07-04 上海和誉生物医药科技有限公司 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用
KR20210018255A (ko) 2018-04-30 2021-02-17 오릭 파마슈티칼스, 인크. Cd73 억제제
EP3810109B1 (en) 2018-05-31 2024-08-07 Peloton Therapeutics, Inc. Compounds and compositions for inhibiting cd73
NZ771648A (en) 2018-06-21 2025-08-29 Antengene Therapeutics Ltd Ectonucleotidase inhibitors and methods of use thereof
WO2020046813A1 (en) 2018-08-27 2020-03-05 Arcus Biosciences, Inc. Cd73 inhibitors
EP3986894A4 (en) 2019-06-20 2023-08-09 Antengene Therapeutics Limited ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF
JP7557522B2 (ja) 2019-07-16 2024-09-27 オリック ファーマシューティカルズ,インク. Cd73阻害剤
TWI830962B (zh) 2019-10-30 2024-02-01 美商歐瑞克製藥公司 Cd73抑制劑

Also Published As

Publication number Publication date
US12454544B2 (en) 2025-10-28
AU2020375914A1 (en) 2022-06-02
BR112022008365A2 (pt) 2023-03-28
KR20220088786A (ko) 2022-06-28
US20210130390A1 (en) 2021-05-06
PL4051688T3 (pl) 2025-09-22
US11028120B2 (en) 2021-06-08
KR20240042573A (ko) 2024-04-02
JP7544815B2 (ja) 2024-09-03
US20230131747A1 (en) 2023-04-27
WO2021087136A1 (en) 2021-05-06
IL308293A (en) 2024-01-01
SI4051688T1 (sl) 2025-08-29
IL308293B2 (en) 2025-12-01
CN114929721B (zh) 2023-07-18
EP4596048A2 (en) 2025-08-06
ZA202204941B (en) 2024-10-30
JP2023500483A (ja) 2023-01-06
US20250034198A1 (en) 2025-01-30
EP4596048A3 (en) 2025-11-19
ES3034168T3 (en) 2025-08-13
KR102727229B1 (ko) 2024-11-06
KR102653726B1 (ko) 2024-04-01
CN116854758A (zh) 2023-10-10
HUE072504T2 (hu) 2025-11-28
CA3159248C (en) 2024-05-28
TW202130353A (zh) 2021-08-16
US20210130389A1 (en) 2021-05-06
US11530236B2 (en) 2022-12-20
IL308293B1 (en) 2025-08-01
JP2024164093A (ja) 2024-11-26
IL292570A (en) 2022-06-01
JP7688769B2 (ja) 2025-06-04
NZ788133A (en) 2024-03-22
IL292570B1 (en) 2023-12-01
US11130778B2 (en) 2021-09-28
US12018043B2 (en) 2024-06-25
IL292570B2 (en) 2024-04-01
DK4051688T3 (da) 2025-06-30
AU2020375914B2 (en) 2024-05-23
CA3159248A1 (en) 2021-05-06
FI4051688T3 (fi) 2025-06-27
EP4051688A4 (en) 2024-03-06
EP4051688B1 (en) 2025-04-23
CN114929721A (zh) 2022-08-19
US20210214387A1 (en) 2021-07-15
TWI830962B (zh) 2024-02-01
BR122023021184A2 (pt) 2024-02-27
EP4051688A1 (en) 2022-09-07
MX2022005256A (es) 2022-08-25
US20220411459A1 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
ES3053198T3 (en) Cd73 inhibitors
IL277006A (en) CD73 inhibitors
IL304348A (en) cd73 inhibitors
PT4051688T (pt) Inibidores de cd73
SG11202106520VA (en) Kif18a inhibitors
GB201905265D0 (en) Inflammasome inhibition
SG11202110534QA (en) Cd73 inhibitors
EP3999517A4 (en) CD73 INHIBITORS
GB201914860D0 (en) Inhibitor compounds
IL292093A (en) Thianopyrimidones as trpa1 inhibitors
GB201819126D0 (en) Inhibitor compounds
IL290087A (en) inhibitory substances
IL276013A (en) pi4kiiibeta inhibitors
SG11202102379XA (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
IL292095A (en) Thianopyrimidones as trpa1 inhibitors
GB201905328D0 (en) Inhibitor compounds
GB201819136D0 (en) Inhibitor compounds
HK40057128A (en) Cd73 inhibitors
HK40047148A (zh) Cd73抑制剂
GB201908044D0 (en) Dopamine-B-Hydroxylase inhibitors
GB201905476D0 (en) MAPA4K4 Inhibitors
GB201905318D0 (en) Inhibitor compounds
IL269414A (en) Rapar for safetyin taneis
GB201905370D0 (en) Elastate inhibition
GB201812462D0 (en) Inhibitors